Factors associated with Adverse Manifestations Post-Immunization (AEFI) COVID-19, Abidjan, Côte d’Ivoire, March-September 2021

  • Vaccine preventable diseases
Export to CSV
In Côte d'Ivoire, the first case of COVID-19 was notified on March 11, 2020. As of August 31, 2021, 55,669 cases have been confirmed with 441 deaths (0, 8 %.) In Africa, more than 70 million people are vaccinated. In Côte d'Ivoire, the vaccination campaign started on March 1, 2021. However, there is a reluctance of the population to vaccination for fear of probable adverse effects. Thus, to respond to this concern, we carried out this study in order to analyze the factors associated with the effects adverse manifestations post-immunization (AEFI) Covid-19.

We conducted a case-control study matched on age, sex and type of vaccines. A case was defined as any person who received at least one dose of anti-COVID-19 vaccine in the two health regions of Abidjan and who presented with a serious or non-serious AEFI from March 1 to September 30, 2021; while a control was a person who was vaccinated in Abidjan during the same period and who did not report AEFI. Data were collected using a semi-structured questionnaire. We performed a conditional logistic regression model to identify factors independently associated with Covid-19 AEFIs using STATA Software®

985 people (353 cases and 632 controls) were registered. The median age was 43 years (36-53). Symptoms commonly experienced were: fever 49.86% (176/353); headaches 42.49% (150/353); profound asthenia 39.94% (141/353) and pain at the injection site 28.90% (102/353) The factors independently associated with AEFI-COVID-19 were: secondary education level (adjusted OR 2.9; 95% CI: 1.1-6.6; p-value 0.031) and married status (adjusted OR: 2.5; 95% CI: 1.1-5.7 p-value 0.034)

The level of secondary education and married status were the factors significantly associated with Covid-19 AEFIs in the Abidjan 1 and 2 health regions. Surveillance, effective management of Covid-19 AEFIs is essential for the proper functioning of the anti-Covid-19 vaccination program.

Please abstracts [at] tephinet [dot] org (email us) if you have any corrections.

If this abstract has been converted into a full article, please abstracts [at] tephinet [dot] org (email us) the link. We would love to help promote your work.